arrow
L

Laura Gramantieri

irccs azienda ospedaliero - universitaria di bologna
H指数:48
被引数:9,133

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Somatic pathogenic mitochondrial DNA mutations independently predict worse prognosis in hepatocellular carcinoma

体细胞致病性线粒体DNA突变独立预测肝细胞癌的不良预后

2026-07-130
OA
Organic Electrochemical Transistors for Real-Time Detection of Immune System Early Activation during Atezolizumab-Bevacizumab Treatment in Hepatocellular Carcinoma

有机电化学晶体管用于肝细胞癌中阿替利珠单抗-贝伐珠单抗治疗期间免疫系统的实时早期激活检测

2026-04-290
OA
Circulating miR-22 Early Predicts TACE Non-Response and Targets WEE1 in Hepatocellular Carcinoma

循环miR-22早期预测TACE无应答并靶向WEE1在肝细胞癌中

Cells
IF5.2
2026-04-190
OAAI
Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer

针对代谢漏洞: rev-erb激动剂SR9009增强索拉非尼在肝癌中的疗效

2026-01-190
OAAI
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma

MiR-22/GLUT1轴诱导肝细胞癌中的代谢重编程和索拉非尼耐药性

2025-04-170
OA
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma

MiR-494通过G6pc靶向诱导代谢变化并调节索拉非尼在肝细胞癌中的反应

2023-06-1017
OAAI
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (October, 10.1007/s11523-020-00757-3, 2020)
2020-10-280
OAAI
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
2020-10-1218
PREAI
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study
2020-09-0110
OAAI
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming
2020-06-0142
OAAI
MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma
2020-04-1550
OAAI